Methods: From an Italian observational database (ARCA) we selected HIV-1-infected drug-naive patients starting two NRTIs and either an INSTI or a bPI, with an available pre-ART resistance genotype. The endpoint was virological failure (VF; plasma HIV-1 RNA .200 copies/mL after week 24). WHO surveillance drug resistance mutations and the Stanford algorithm were used to classify patients into three resistance categories: no TDR (A), TDR but fully-active ART prescribed (B), TDR and at least low-level resistance to one or more prescribed drug (C).
Introduction
Transmission of drug-resistant HIV-1 is a well-known phenomenon detected in 8% of newly diagnosed individuals in Europe, with significant differences depending on viral subtype, geographic area, risk group and migration timeline. [1] [2] [3] Transmitted drug resistance (TDR) is increasing in southern and eastern Africa, particularly to the antiretroviral class of NNRTIs, a cornerstone of recommended first-line ART in these countries. 4 TDR may significantly influence the outcome of ART, [5] [6] [7] and therefore drug resistance testing is recommended when choosing the first-line regimen in resource-rich countries. [8] [9] [10] [11] The risk of virological failure (VF) was increased in patients harbouring pretreatment drug resistance to at least one of the prescribed drugs in NNRTI-based regimens, as compared with individuals without pretreatment drug resistance, but not in patients with pretreatment drug resistance and fully active ART. 12 International panels currently recommend first-line ART regimens including integrase strand transfer inhibitors (INSTIs) or boosted protease inhibitors (bPIs), because of their efficacy and tolerability. [9] [10] [11] However, in the absence of resistance testing, some authors suggest use of bPIs due to their higher genetic barrier compared with INSTIs. 8 Indeed, the influence of TDR on the 5, 6, [13] [14] [15] [16] The aim of this study was to examine the impact of TDR on response to first-line regimens in naive patients starting INSTIbased, three-drug antiretroviral therapy. As a reference, we also analysed the impact of TDR on the efficacy of bPI-based regimens.
Patients and methods
Protease, reverse transcriptase and integrase genotype sequences from treatment-naive HIV-1-infected adults starting a first-line therapy that included two NRTIs plus one INSTI or two NRTIs plus one bPI from January 2008 to June 2016 were selected from the Antiviral Response Cohort Analysis (ARCA), an Italian multicentre virological and clinical database (http://www.dbarca.net), including cases with at least one plasma HIV-1 RNA value after 24 weeks of follow up.
Plasma genotypic resistance was determined by Sanger's population sequencing using commercially available or homebrew systems. TDR was defined as the detection of at least one mutation among those included in the WHO-recommended surveillance drug resistance mutation (SDRM) list for NRTIs, NNRTIs, bPIs 17 and those included in the Stanford HIVdb SDRM Worksheet for INSTIs (https://hivdb.stanford.edu/pages/SDRM.worksheet. INI.html). The Stanford HIVdb algorithm (version 8.4, https://hivdb.stan ford.edu) was used to classify patients into three resistance categories:
4 absence of TDR mutations (category A); presence of TDR mutations but use of a fully active ART regimen (category B); or presence of TDR mutations and at least low-level resistance to at least one prescribed drug (category C). HIV-1 subtyping was available: this was automatically performed by BLAST upon sequence upload and further analysed by phylogenetic analysis in the event of ,95% homology to the pure subtype reference panel.
The primary outcome was VF, defined as a plasma HIV-1 RNA .200 copies/mL after week 24, ignoring treatment changes. Survival analysis, using Kaplan-Meier curves, was employed to estimate the probability of VF. Predictors of VF were investigated using Cox regression models. All analyses were performed using SPSS version 22 (IBM, Armonk, NY, USA).
Ethics
The database was approved by the central Ethics Committee (21 July 2014) and by the Ethics Committees of the individual clinics centres, and written informed consent was obtained from all patients before participation. The study was performed in accordance with the ethics guidelines of the Declaration of Helsinki (7th revision).
Results
The study included a total of 1365 patients: 1205 (88.3%) treated with two NRTIs plus one bPI, and 160 (11.7%) treated with two NRTIs plus one INSTI. The baseline characteristics of the patients are shown in Table 1 . The main differences between the two treatment groups were a higher baseline plasma HIV-1 RNA and lower baseline and nadir CD4 cells counts in the bPI group. Patients in the INSTI group were more frequently located in southern Italy and started therapy more recently. The most frequently prescribed INSTI was raltegravir (39%), followed by dolutegravir (35%) and elvitegravir/cobicistat (26%). The most frequently used bPI was lopinavir/ritonavir (41%), followed by atazanavir/ritonavir (30%) and darunavir/ritonavir (28%).
The overall prevalence of any TDR mutation was 18.4%, without differences between groups. NRTI, NNRTI, PI and INSTI resistance mutations were detected in 83 (6.1%), 171 (12.5%), 35 (2.6%) and 0 (0.0%) patients, respectively. Although there was a similar prevalence of NRTI TDR in the two treatment groups, NNRTI TDR was more frequent in the bPI group (13.1% versus 8.1% in the INSTI group, P " 0.043), whereas PI TDR was less frequent in the PI group (2.1% versus 6.3%, P " 0.05).
During a median follow-up time of 96 weeks (IQR 54-110) VF occurred in 195 individuals in the PI group and in 11 in the INSTI group, with an estimated cumulative probability at 48 weeks of 11% (95% CI 10.1%-11.9%) and 7.7% (95% CI 5.4%-10%), respectively (P " 0.01 by log-rank test).
In the INSTI group, resistance category C showed a significantly higher estimated probability of 48 week VF (50%, 95% CI 30%-70%) versus categories A (6%, 95% CI 4%-8%) and B (5%, 95% CI 1%-10%) (P , 0.001). By contrast, in the bPI group the estimated probability of VF at 48 weeks was similar in all three categories: category A 11% (95% CI 10%-12%), category B 12% (95% CI 10%-14%) and category C 9% (95% CI 5%-13%) (P " 0.390) (Figure 1 ). In the INSTI group, but not in the bPI group, resistance category C [versus A, adjusted hazard ratio (aHR) 12.6, 95% CI 3.2-49.8, P , 0.001] and nadir CD4 (!100 cells/mm 3 higher, aHR 0.6, 95% CI 0.4-0.9, P " 0.03) independently predicted VF. In the bPI group, in a multivariable model adjusting for gender, nationality, tenofovir/emtricitabine use, viral subtype, type of bPI and TDR to NRTI, independent predictors of VF were zidovudine/lamivudine use (aHR 2.3, 95% CI 1.4-3.9, P " 0.002), calendar year (per 1 year more recent, aHR 0.9, 95% CI 0.8-0.9, P " 0.04) and lopinavir/ritonavir use (versus darunavir/ritonavir, aHR 1.4, 95% CI 1.0-2.0, P " 0.03).
Eleven patients, mostly (9/11) harbouring viral subtype B, experienced VF in the INSTI group: 8 were on treatment with raltegravir, 2 with dolutegravir and 1 with elvitegravir/cobicistat. At failure, plasma HIV-1 RNA ranged between 210 and 213200 copies/mL and higher values were detected in patients with lower baseline CD4 counts. Three of the 11 failing INSTI carried TDR to NRTI: two bearing M41L and one M184V, whereas none carried resistance to INSTIs; the regimens included tenofovir/emtricitabine as backbone with raltegravir in two patients and dolutegravir in one.
Seven patients changed antiretroviral therapy after VF, with six patients switching to a bPI-based regimen. Among those that continued the previous regimen, three reached virological resuppression at the subsequent visit and one was lost to follow up (Table S1 , available as Supplementary data at JAC Online).
Discussion
The key finding of this study is the impact of pretreatment HIV-1 drug resistance on the risk of VF in patients initiating ART with two NRTIs plus an INSTI. Despite the small number of cases, the magnitude of this effect was very relevant, with a .10-fold higher adjusted hazard of VF compared with patients without TDR. To our knowledge, this is the first report showing a significant impact of TDR to NRTI on the activity of first-line regimens with two NRTI plus an INSTI, the current standard of care of first-line ART. Indeed, previous observational studies on the influence of TDR did not include INSTI-based regimens and clinical trials with INSTI excluded patients with TDR. 1, 2, 5, 13, 18, 19 A recent post hoc analysis from the SAILING trial conducted in treatment-experienced, INSTI-naive patients with resistance to two or more classes of antiretroviral drugs showed a lower VF rate Transmitted HIV-1 drug resistance and efficacy of first-line ART JAC in subjects receiving dolutegravir compared with raltegravir, even when the backbone was suboptimal or NRTI resistance was present at baseline. 20 The authors suggested the different outcomes might be due to a potency difference, a higher barrier to resistance or a difference in adherence with these two distinct INSTIs. 20 Interestingly, in the same group, TDR not affecting the activity of the prescribed drugs did not have any impact on virological efficacy. This finding is reassuring, suggesting that even in the presence of TDR, INSTI-based first-line regimens are effective when fully active accompanying drugs are selected based on the resistance test result.
The overall prevalence of TDR in this cohort was 18.4%, higher than usually reported in European cohorts, and was primarily driven by NNRTI resistance. [1] [2] [3] This could be explained by the fact that detection of TDR may have resulted in the use of high-genetic barrier bPI therapy, resulting in an overestimate of TDR in this population. In addition, bPI-based regimens were preferentially prescribed to more challenging patients, such as those with higher baseline viral load and lower CD4 counts, possibly explaining at least in part the higher virological efficacy of INSTI-based as compared with PI-based regimens observed here. The relatively long period of observation may also explain some of the Spertilli Raffaelli et al. imbalances observed between the two treatment groups, reflecting drug availability over time. In the PI group, zidovudine/lamivudine and lopinavir/ritonavir use were associated with more frequent VF, suggesting a crucial role of their lower tolerability and efficacy.
The main limitations of this study are the retrospective nature, the small number of patients treated with INSTIs and the relatively limited sample size in the INSTI treatment groups, particularly for dolutegravir, which did not provide sufficient power to detect differences among drugs with different genetic barriers. Future analyses that include a larger and balanced INSTI group are necessary to confirm our findings and clarify whether NRTI TDR has a different impact on virological efficacy using different types of INSTI.
In conclusion, our findings support the need for pretreatment drug resistance testing of NRTIs in order to optimize antiretroviral therapy in patients starting first-line INSTI-based regimens. Transmitted HIV-1 drug resistance and efficacy of first-line ART
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